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Intracavitary brachytherapy (ICBT) in combination with external-beam radio-
therapy (EBRT) has long been accepted as the standard treatment for uterine
cervical cancer.
1 ICBT is used to deliver high radiation doses to the clinical target
volume (CTV) by replacing radioactive sources that are in direct contact with the
gross tumor. Traditionally, it is known that a cure is rarely achieved without a
high dose of radiation delivered by ICBT. However, the clinical reality is that the
treatment with EBRT alone is needed in patients where ICBT is not feasible due
to a failure to insert a tandem, a narrow vagina, relapses at the cervical stump, or
the refusal of the patient. Interstitial brachytherapy is often helpful in these cases,
but it involves invasive procedures and its success is highly dependent on the
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Purpose: The purpose of this study is to evaluate the clinical results of treatment with a high dose of 3-dimensional
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Materials and Methods: Between January 2001 and December 2004, 10 patients with cervical cancer were treated
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INTRODUCTIONability of the operator.
2
Replacing the use of ICBT with an EBRT boost should
be applicable with the advances of the conformal radiation
delivery technique. Some innovative researchers have
challenged the use of ICBT by using EBRT instead with
modest results obtained.
3-8 However, in these studies, severe
complications were observed in some patients. While the
use of ICBT can keep a fixed geometry between the CTV
and the applicator, minimizing the error in delivering the
planned dose distribution to the target, EBRT has shortcom-
ings with regards to setup errors and possible internal
organ motion. To overcome these shortcomings, a fluoro-
scopic real-time tumor tracking radiotherapy (RTRT)
system was developed and applied for the treatment of
pelvic malignancies.
9-11 We have previously reported the
feasibility and accuracy of the use of a high dose three-
dimensional conformal boost (3DCB) with the RTRT
system in patients with gynecologic malignancies.
12 The
RTRT system was useful to reduce the uncertainty due to
external and internal error, confirming that a planning
target volume (PTV) margin of 7-8 mm should be applied
in the protocol setting. 
To maintain similar therapy conditions to the tumor as
with ICBT, the daily dose and the overall treatment time with
the use of a high dose 3DCB are needed to be kept similar as
with ICBT. The usual fractionation scheme for ICBT in our
institution was 25 Gy/5 fractions or 35 Gy/7 fractions, with a
daily fraction of 5 Gy and two fractions per week.
13 Using the
RTRT technology, we applied a hypofractionated 3DCB
mimicking ICBT in patients with uterine cervical cancer that
were unable to undergo ICBT after EBRT. 
In this report, early clinical results of cervical cancer
patients treated with high dose 3DCB using the RTRT
system were evaluated. The possibility of high precision
conformal therapy using the RTRT technology as an alter-
native to ICBT is discussed.
Patients
Between January 2001 and December 2004, 10 patients
with cervical cancer were treated with a high dose 3DCB
using the RTRT system without ICBT. Before starting the
3DCB, we explained to the patients that the standard defi-
nitive radiotherapy (RT) method was a combination of
EBRT and ICBT, but the use of a high dose 3DCB with
the RTRT system could be an option in patients unable to
undergo ICBT. All patients decided to receive a high dose
3DCB. Pre-treatment evaluation included a complete history
and physical examination, biopsy, abdominal and pelvic
computed tomography (CT), and chest X-ray. Lymph
node sampling was not performed routinely. Threshold
value for identifying metastatic LNs was 10 mm short axis
diameter. Patients with an outside pathology diagnosis had
their pathology slides reviewed at our institution. For stag-
ing purposes, a radiation oncologist and a gynecologic
oncologist performed a physical examination. Staging was
performed according to the International Federation of
Gynecology and Obstetrics (FIGO) classification.
14
Five patients with newly diagnosed uterine cervical
cancer, two patients with a stump carcinoma, and three
patients with a vault recurrence were included in the anal-
ysis. Three patients with a vault recurrence received a
radical hysterectomy due to FIGO stage I cervical cancer.
Postoperative radiotherapy was added in 1 patient (patient
2). Two patients with a stump carcinoma received a hys-
terectomy due to myoma. The median age of the patients
was 64 years (range, 32-78 years). The patient and tumor
characteristics are summarized in Table 1.  
Hee Chul Park, et al.
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MATERIALS AND METHODS
Table 1.Characteristics of 10 LN (-) Patients
Patient Age 
KPS Site Histology
FIGO Tumor  size 
number (yrs) stage (cc)
1 32 90 Cervix Small IIB 80
2 65 90 Vault Squamous IIB 30
3 35 90 Cervix Adenosarcoma IIIB 192
4 70 80 Cervix Squamous IIIB 240
5 63 90 Vault Squamous IIB 24
6 69 80 Cervix Squamous IIIB 80
7 57 90 Vault Squamous IIIB 40
8 67 80 Cervix Squamous IIIB 64
9 60 90 Stump Squamous IIA 18
10 78 70 Stump Squamous IIA 20
LN, lymph node; KPS, Karnofsky performance score; FIGO, International Federation of Gynecology and Obstetrics; Small, small cell 
carcinoma; Squamous, squamous cell carcinoma.Treatment planning and treatment
The general principles of treatment planning and delivery
were reported in previous studies.
9-12 If ICBT and interstitial
RT were abandoned and the patients agreed to enter this
study, three radiopaque gold markers were implanted in or
near the tumor by a trans-vaginal approach using specially
made equipment (Medikit, Tokyo, Japan). After the gold
markers were implanted, a planning CT scan was performed
using a 1 mm slice thickness for the level involving the
tumor mass and three gold markers (Fig. 1). The treatment
planning was performed using the Focus
® system (CMS,
St. Louis, MO USA). The CTV encompassed the gross
tumor volume with a safety margin. Usually, a safety
margin of up to 5 mm was taken. In lateral directions, a
safety margin of 8 mm was used. For the PTV, a 7-8 mm
margin from the CTV was applied. After finishing the
treatment planning, the coordinates of the target volume,
isocenter, and three markers were registered and sent to the
RTRT system. After adjusting the patient set-up using the
RTRT system, the treatment was delivered. We checked
the intrafractional movement of the marker several times
during each treatment while the gantry was moving to the
next position. The details of set-up and the radiation deli-
very procedure in our protocol setting were reported pre-
viously.
12
The treatment characteristics of the patients are summa-
rized in Table 2. Nine patients received a whole pelvis RT
with a median dose of 50 Gy (range, 40-50 Gy). Midline
shielding was performed in six patients after a dose of 40
Gy. The median dose of the 3DCB was 30 Gy (range, 25-
30 Gy). The 3DCB was delivered by a 3D-conformal tech-
nique (7 patients) and forward planning intensity-modulated
radiation therapy (IMRT) technique (3 patients). Eight
patients received the 3DCB twice a week with a daily frac-
tion of 5 Gy, as with the ICBT fractionation scheme of our
institution.
12 Two patients received 2.5 Gy daily fractions
3-4 times a week. The treatment volume typically covered
the gross tumor and the area of parametrium invasion.
Concurrent chemotherapy with weekly cisplatin was admi-
nistered to three patients. 
Follow-up
Patients were scheduled for follow-up visits every 3 months.
We determined the dates of local and distant failure using
imaging studies, primarily abdomen and pelvic CT scans,
which were performed at approximately three-month inter-
vals during the initial two years of follow-up. 
End points and statistical analysis
The major endpoints of this study were tumor response,
overall survival (OS), local failure free survival (local
failure, defined as any recurrence within the RT volume),
and distant metastasis free survival. Nodal recurrences
were also evaluated. Late toxicity was graded according to
the Radiation Therapy Oncology Group/European Organi-
zation for Research and Treatment of Cancer late radiation
High Dose 3DCB for Cervical Cancer
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Fig. 1. Fluoroscopy and planning CT image of three gold markers placed in a
patient. 
Table 2. Treatment Characteristics of the Patients
Patient Pelvis
Midline 3DCB 3DCB  3DCB
3DCB Concurrent
number dose (Gy)
shielding dose fraction  fractionation
technique CTX
at (Gy) (Gy) size (Gy) (number/weekly)
1 50 40 30 5 2 3DCRT Yes
2 0 - 30 2.5 3 3DCRT -
3 50 40 25 2.5 4 3DCRT Yes
4 50 40 30 5 2 FIMRT -
5 50 40 30 5 2 3DCRT -
6 50 - 30 5 2 3DCRT -
7 50 40 30 5 2 FIMRT -
8 50 - 30 5 2 FIMRT Yes
9 50 - 30 5 2 3DCRT -
10 40 - 30 5 2 3DCRT -
3DCB, 3-dimensional conformal boost; 3DCRT, 3-dimentional conformal radiation therapy; FIMRT, forward planning intensity-modulated 
radiation therapy; CTX, chemotherapy.Hee Chul Park, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 96
morbidity scoring scheme.
15 
The duration of the follow-up period was calculated
from the date of the first visit to our clinic. The duration of
survival was calculated from the day of commencing RT.
The survival time was censored at the time of the last
follow-up on record if death was not observed. Dates of
local and distant failure were determined using imaging
studies. Survival probabilities were estimated non-para-
metrically using the Kaplan-Meier’s product limit method.
16 
Clinical response
The endpoints are summarized in Table 3. Of 10 patients,
complete response (CR) of the tumor was achieved in nine
patients (90%), and one patient had a partial response (PR).
Therefore, the response rate (CR + PR) was 100%. Fig. 2
shows the tumor response in case 5.
Disease control and survival 
All patients were still alive at the time of analysis and the
median follow-up was 17.6 months (range 4.9-27.3 months)
(Fig. 3). Four patients were alive without disease, and six
patients were alive with disease. Four patients had local
failure and the crude rate of local control was 60%. Two
patients had distant metastases and the crude rate of distant
disease control was 80%. One patient had a liver and bone
metastasis and the other patient had a metastasis to the
para-aortic lymph node and the adrenal gland. The actuarial
1 year and 2 year local failure free survival was 78.8% and
54%, respectively. The actuarial 1 year and 2 year distant
metastasis free survival was 90% and 72%, respectively.
Treatment toxicities 
All patients tolerated the 3DCB very well and no severe
adverse effects were encountered. However, acute toxicity
of grade 1 diarrhea was seen in five patients. Late toxicity
of grade 2 rectal hemorrhage was seen in one patient. A
subcutaneous abscess was encountered in one patient 6
months after the completion of RT. 
RESULTS
Table 3.Summary of the Treatment Results
Patient Tumor Local Distant
Complications
FU periods Current
number response recurrence metastasis (months) status
1 CR - Liver, bone G2 rectal 16.9 AWD
2 CR - - - 23.7 NED
3 PR Y - - 21.0 AWD
4 CR Y - - 18.2 AWD
5 CR - - - 27.3 NED
6C R- -
Subcutaneous 
12.5 NED
abscess
7 CR Y - - 14.9 AWD
8C R-
PA node, 
- 21.7 AWD
adrenal gland
9 CR Y - - 12.5 AWD
10 CR - - - 5.0 NED
FU, follow-up; CR, complete response; PR, partial response; Y, yes; PA, para-aortic; G, grade; AWD, alive with disease; NED, no evidence 
of disease.
Fig. 2.Clinical response of the tumor in case 5.
Fig. 3.Survival plotting.It is well known that ICBT is an essential component of
RT for uterine cervical cancer.
1 With a direct contact to the
tumor, ICBT effectively delivers the tumoricidal dose while
sparing the surrounding normal tissue. However, a small
but definite proportion of patients are not suitable to undergo
ICBT for several clinical reasons. Thus, we intended to
treat those patients with a high dose 3DCB replacing the
ICBT portion of the entire treatment. The RTRT technology
provides the effective tools to realize individual-based,
precise adaptive irradiation for moving, shrinking, and
deforming targets, such as gynecologic malignancies. In an
effort to mimic the ICBT portion of the treatment, we
applied RTRT technology in the current protocol settings. 
The treatment results of the use of the high dose 3DCB
in the present study were not satisfying. The local failure
free survival was relatively low at 2 years. Though there
were six patients with disease recurrence, the OS was still
100% because of the short-term follow-up. It is thought
that a further follow-up with more patients could confirm
the treatment results and the effectiveness of our study
protocol. In our study, the adaptive set-up of patients using
the RTRT system was proved as a safe adjunct showing a
minimal level of late complications. It seems that further
escalation of the 3DCB dose could be pursued safely.
Among patients with local failure, three patients had FIGO
IIIB disease and two patients had a large tumor size
(patient 3 and 4). The escalation of the 3DCB dose is being
evaluated to improve local control for these patients with
locally advanced diseases. 
Some investigators have performed definitive external
radiation therapy without ICBT for uterine cervical can-
cer.
3,4,6 Table 4 shows the treatment results of these studies.
Matsuura, et al.
3 used concomitant boost with accelerated
hyperfractionation to shorten the overall treatment time as
compared to ICBT. However, due to a small study popula-
tion and short term follow-up, the level of local control
(85.7%) and survival comparable to the results of standard
treatment has not yet been confirmed. The particle radiation
therapy series has shown better long-term local control and
survival.
4,6 However, these studies showed a significant
level of late morbidity. Detrimental set-up errors and
internal organ motion contributed to late morbidity result-
ing from a high dose to the surrounding normal tissues.
The use of a better adaptive set-up strategy is needed for
the successful execution of definitive EBRT for gyneco-
logic malignancies. 
Except in the clinical situation in which proper ICBT
cannot be performed, the use of ICBT is being challenged
in many studies. Several researchers have performed a
dosimetric comparison between the use of IMRT and
ICBT in terms of dose homogeneity and target coverage.
17-20
Chan, et al.
21 compared different EBRT techniques as an
alternative to ICBT. These investigators showed that the
use of IMRT could improve target coverage and reduce
the dose to critical structures. Moreover, when used in
conjunction with a suitable immobilization system, IMRT
may provide an alternative to ICBT. The average minimum
tumor dose was significantly greater and the mean percent
tumor volume receiving more than the prescription dose
was higher with IMRT. The mean volume at the tolerance
limit decreased for the bladder. These advantages of IMRT
High Dose 3DCB for Cervical Cancer
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DISCUSSION
Table 4. Outcomes for Various Studies Evaluating the Role of EBRT to Replace ICBT
Author Patients FIGO
Treatment
Local
Survival Complication
(yr) (No.) Stage control
Photon + Proton beam therapy
75%  59% 24% grade 2 - 4 GI complication
Kagei, et al.
6 25 IIB - IVA Pelvis with X-ray 50.4 Gy / 28 Fx
(5 yr) (10 yr) 8% grade 2 - 4 complication
Tumor boost 37 - 101 Gy
Carbon ion radiotherapy
45 - 79% 37 - 43% 25% Grade 2 - 4 GI complication
Kato, et al.
4 44 IIIB - IVA Pelvis 35.2 - 44.8 GyE
(5 yr) (5 yr) 9.1% Grade 2 GU complication
Tumor Boost 24 - 28 GyE
Concomittant boost AHF
85.7% 85.7% 28.6% Grade 2 rectal
Matsuura, et al.
3 7 IB - IVA Pelvis 45 Gy / 25 Fx
(2 yr) (2 yr) complication
Tumor boost 21 - 28 Gy / 15 Fx
High dose 3DCB using RTRT
54%  72%  10% Grade 2 rectal complication
Present study 10 IIA - IIIB Pelvis 40 - 50 Gy / 20 - 25 Fx
(2 yr) (2 yr) 10% Subcutaneous abscess
Tumor boost 30 Gy / 6 Fx
EBRT, external beam radiation therapy; ICBT, intracavitary brachytherapy; FIGO, International Federation of Gynecology and Obstetrics; Fx, fractions; Gy, gray; 
GyE, gray equivalent; AHF, accelerated hyperfractionation; 3DCB, 3-dimensional conformal boost; RTRT, real-time tracking radiotherapy; GI, gastrointestinal; GU,
genitourinary.over ICBT are accentuated, especially in large volume
tumors. 
A weakness of ICBT is that tumors may have a particular
size or geometry that places much of the tumor volume in
peripheral under-dosed regions. Furthermore, critical
structures may be over-dosed because of their proximity to
the radioactive sources. To optimize the ICBT planning at
best, some recommendations have been published on the
use of 3-dimensional image-based treatment planning in
ICBT.
22-24 However, even with the best optimization, it
seems that the weakness of ICBT could not be removed
completely due to the interplay between the tumor shape
and the limited degree of freedom of the applicator geo-
metry. Chao, et al.
25 investigated the consequences of utero-
sacral space involvement in patients with stage IIIB cervical
cancer. These investigators concluded that the combination
of ICBT and EBRT did not deliver an adequate dose to the
tumor in the uterosacral space, and an improved dose
delivery regimen should be investigated. 
Non-uniform doses are unavoidable in ICBT resulting in
a hot spot and cold spot that develop in the tumor. This
inhomogeneity in the dose delivered by the ICBT is both
advantageous and disadvantageous for tumor control.
Since a dose deficit to a 1% sub-volume of the target larger
than 20% of the prescription dose may lead to serious loss
of tumor control probability (TCP), even if  80% of the target
receives a 10% boost, particular attention is required for
small-volume cold regions in the target.
26 Once the target is
covered adequately, the use of deliberate non-uniform doses
may increase the TCP. Tome, et al.
26,27 reported that up to
30% of a sub-volume boost to the 60-80% of the target
volume appeared worthwhile or necessary to maximize the
TCP. IMRT gives the best scenario of inhomogeneous
irradiation with adequate target coverage. The simultaneous
integrated boost (SIB) technique of IMRT was success-
fully applied in the treatment of head and neck cancer.
28
Thus, IMRT using RTRT technology can be the best
modality for EBRT to replace ICBT in the treatment of
cervical cancer. We have reported the feasibility of the use
of synchronized IMRT using the RTRT system. Unlike the
thoracic and upper gastrointestinal malignancies in which a
narrow gating window is needed, it is thought that this
technique could be applied successfully in the treatment of
pelvic malignancies without an excess fluoroscopy dose to
the skin surface.
29
In conclusion, although more patients with longer follow-
up periods are needed to evaluate the usefulness of high
dose 3DCB, especially to determine the long-term toxicity
level, our results suggest that a high dose of 3DCB replacing
ICBT in the treatment of gynecologic malignancies is safe
and feasible where ICBT is unable to be performed. To
improve local control, the escalation of the radiation dose
should be pursued. The use of synchronized IMRT with
the RTRT system is a promising therapy and needs to be
investigated further. 
This work was supported in part by a grant from the Japan-
ese Ministry of Education, Culture, Sports, Science and
Technology.
1. Park HC, Suh CO, Kim GE. Fractionated high-dose-rate brachy-
therapy in the management of uterine cervical cancer. Yonsei
Med J 2002;43:737-48.
2. Hughes-Davies L, Silver B, Kapp DS. Parametrial interstitial
brachytherapy for advanced or recurrent pelvic malignancy: the
Harvard/Stanford experience. Gynecol Oncol 1995;58:24-7.
3. Matsuura K, Tanimoto H, Fujita K, Hashimoto Y, Murakami Y,
Kenjo M, et al. Early clinical outcomes of 3D-conformal radio-
therapy using accelerated hyperfractionation without intracavitary
brachytherapy for cervical cancer. Gynecol Oncol 2007;104:11-4.
4. Kato S, Ohno T, Tsujii H, Nakano T, Mizoe JE, Kamada T, et al.
Dose escalation study of carbon ion radiotherapy for locally
advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol
Phys 2006;65:388-97.
5. Mollá M, Escude L, Nouet P, Popowski Y, Hidalgo A, Rouzaud
M, et al. Fractionated stereotactic radiotherapy boost for gyneco-
logic tumors: an alternative to brachytherapy? Int J Radiat Oncol
Biol Phys 2005;62:118-24.
6. Kagei K, Tokuuye K, Okumura T, Ohara K, Shioyama Y,
Sugahara S, et al. Long-term results of proton beam therapy for
carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys
2003;55:1265-71.
7. Ulmer HU, Frischbier HJ. Treatment of advanced cancers of the
cervix uteri with external irradiation alone. Int J Radiat Oncol
Biol Phys 1983;9:809-12.
8. Castro JR, Issa P, Fletcher GH. Carcinoma of the cervix treated
by external irradiation alone. Radiology 1970;95:163-6.
9. Shirato H, Shimizu S, Kunieda T, Kitamura K, van Herk M, Kagei
K, et al. Physical aspects of a real-time tumor-tracking system for
gated radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1187-95.
10. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R,
Fujita K, et al. Reduction in acute morbidity using hypofrac-
tionated intensity-modulated radiation therapy assisted with a
fluoroscopic real-time tumor-tracking system for prostate cancer:
preliminary results of a phase I/II study. Cancer J 2003;9:268-76.
11. Shimizu S, Shirato H, Kitamura K, Shinohara N, Harabayashi T,
Tsukamoto T, et al. Use of an implanted marker and real-time
tracking of the marker for the positioning of prostate and bladder
cancers. Int J Radiat Oncol Biol Phys 2000;48:1591-7.
12. Yamamoto R, Yonesaka A, Nishioka S, Watari H, Hashimoto T,
Uchida D, et al. High dose three-dimensional conformal boost
(3DCB) using an orthogonal diagnostic X-ray set-up for patients
with gynecological malignancy: a new application of real-time
tumor-tracking system. Radiother Oncol 2004;73:219-22.
Hee Chul Park, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 98
ACKNOWLEDGEMENTS
REFERENCESHigh Dose 3DCB for Cervical Cancer
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 99
13. Kagei K, Shirato H, Nishioka T, Kitahara T, Suzuki K, Tomita
M, et al. High-dose-rate intracavitary irradiation using linear
source arrangement for stage II and III squamous cell carcinoma
of the uterine cervix. Radiother Oncol 1998;47:207-13.
14. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO
staging classifications and clinical practice guidelines in the
management of gynecologic cancers. FIGO Committee on
Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation
Therapy Oncology Group (RTOG) and the European Organization
for Research and Treatment of Cancer (EORTC). Int J Radiat
Oncol Biol Phys 1995;31:1341-6.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958;63:457-81.
17. Aydogan B, Mundt AJ, Smith BD, Mell LK, Wang S, Sutton H,
et al. A dosimetric analysis of intensity-modulated radiation
therapy (IMRT) as an alternative to adjuvant high-dose-rate
(HDR) brachytherapy in early endometrial cancer patients. Int J
Radiat Oncol Biol Phys 2006;65:266-73.
18. Wahab SH, Malyapa RS, Mutic S, Grigsby PW, Deasy JO,
Miller TR, et al. A treatment planning study comparing HDR and
AGIMRT for cervical cancer. Med Phys 2004;31:734-43.
19. Schefter TE, Kavanagh BD, Wu Q, Tong S, Newman F, McCourt
S, et al. Technical considerations in the application of intensity-
modulated radiotherapy as a concomitant integrated boost for
locally-advanced cervix cancer. Med Dosim 2002;27:177-84.
20. Low DA, Grigsby PW, Dempsey JF, Mutic S, Williamson JF,
Markman J, et al. Applicator-guided intensity-modulated radiation
therapy. Int J Radiat Oncol Biol Phys 2002;52:1400-6.
21. Chan P, Yeo I, Perkins G, Fyles A, Milosevic M. Dosimetric
comparison of intensity-modulated, conformal, and four-field
pelvic radiotherapy boost plans for gynecologic cancer: a
retrospective planning study. Radiat Oncol 2006;1:13.
22. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD,
Petereit D. The American Brachytherapy Society recommen-
dations for high-dose-rate brachytherapy for carcinoma of the
cervix. Int J Radiat Oncol Biol Phys 2000;48:201-11.
23. Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Bra-
bandere M, Dimopoulos J, et al. Recommendations from gynae-
cological (GYN) GEC ESTRO working group (II): concepts and
terms in 3D image-based treatment planning in cervix cancer
brachytherapy-3D dose volume parameters and aspects of 3D
image-based anatomy, radiation physics, radiobiology. Radiother
Oncol 2006;78:67-77.
24. Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Braban-
dere M, Dimopoulos J, et al. Recommendations from Gynaeco-
logical (GYN) GEC-ESTRO Working Group (I): concepts and
terms in 3D image based 3D treatment planning in cervix cancer
brachytherapy with emphasis on MRI assessment of GTV and
CTV. Radiother Oncol 2005;74:235-45.
25. Chao KS, Williamson JF, Grigsby PW, Perez CA. Uterosacral
space involvement in locally advanced carcinoma of the uterine
cervix. Int J Radiat Oncol Biol Phys 1998;40:397-403.
26. Tomé WA, Fowler JF. On cold spots in tumor subvolumes. Med
Phys 2002;29:1590-8.
27. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes.
Int J Radiat Oncol Biol Phys 2000;48:593-9.
28. Lee SW, Back GM, Yi BY, Choi EK, Ahn SD, Shin SS, et al.
Preliminary results of a phase I/II study of simultaneous modulat-
ed accelerated radiotherapy for nondisseminated nasopharyngeal
carcinoma. Int J Radiat Oncol Biol Phys 2006;65:152-60.
29. Shirato H, Oita M, Fujita K, Watanabe Y, Miyasaka K. Feasi-
bility of synchronization of real-time tumor-tracking radiotherapy
and intensity-modulated radiotherapy from viewpoint of exces-
sive dose from fluoroscopy. Int J Radiat Oncol Biol Phys 2004;
60:335-41.